- Home
- NTHI vs CRBU Comparison
NTHI vs CRBU Comparison
Compare NTHI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- CRBU
- Stock Information
- Founded
- NTHI 2008
- CRBU 2011
- Country
- NTHI United States
- CRBU United States
- Employees
- NTHI N/A
- CRBU N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- NTHI Health Care
- CRBU Health Care
- Exchange
- NTHI Nasdaq
- CRBU Nasdaq
- Market Cap
- NTHI 211.9M
- CRBU 179.7M
- IPO Year
- NTHI N/A
- CRBU 2021
- Fundamental
- Price
- NTHI $10.10
- CRBU $2.44
- Analyst Decision
- NTHI
- CRBU Strong Buy
- Analyst Count
- NTHI 0
- CRBU 3
- Target Price
- NTHI N/A
- CRBU $6.67
- AVG Volume (30 Days)
- NTHI 42.8K
- CRBU 1.1M
- Earning Date
- NTHI 11-19-2025
- CRBU 11-07-2025
- Dividend Yield
- NTHI N/A
- CRBU N/A
- EPS Growth
- NTHI N/A
- CRBU N/A
- EPS
- NTHI N/A
- CRBU N/A
- Revenue
- NTHI $59,990.00
- CRBU $9,121,000.00
- Revenue This Year
- NTHI N/A
- CRBU $8.06
- Revenue Next Year
- NTHI N/A
- CRBU N/A
- P/E Ratio
- NTHI N/A
- CRBU N/A
- Revenue Growth
- NTHI N/A
- CRBU N/A
- 52 Week Low
- NTHI $3.20
- CRBU $0.66
- 52 Week High
- NTHI $25.00
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- CRBU 45.99
- Support Level
- NTHI N/A
- CRBU $2.35
- Resistance Level
- NTHI N/A
- CRBU $2.59
- Average True Range (ATR)
- NTHI 0.00
- CRBU 0.20
- MACD
- NTHI 0.00
- CRBU -0.06
- Stochastic Oscillator
- NTHI 0.00
- CRBU 2.71
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.